Finn
RVTY Life Sciences Tools · Healthcare · Diagnostics · Thesis updated November 8, 2026

Growth accelerates as AI demand broadens across the portfolio

01 Running thesis

A cleaner story meets a new catalyst

Revvity is proving its turnaround plan. The company signed a definitive agreement to sell its China Immunodiagnostics business. This removes a policy heavy overhang and firms up an exit timeline for late 2027. Stripping this out leaves a company better positioned to grow, which is already showing up in the numbers.

Profitability fears from earlier in the year are fading entirely. The core Life Sciences segment returned to 9 percent organic growth in the third quarter, driven by a broad recovery in pharma and biotech end markets. The Diagnostics unit also shined. Excluding the China business, Diagnostics operating margins crossed 30 percent in the quarter.

A new structural growth driver is taking shape. Artificial intelligence generates biological hypotheses, but those ideas need real world validation. This creates a lab in the loop workflow that directly benefits Revvity. Demand for the company's instruments is now expanding beyond high content screening into detection and high throughput screening.

The bear case rests on timing and backlog execution. Some of the third quarter reagent strength was aided by the timing of bulk screening orders, which may flatter the underlying run rate. If the large instrument backlog normalizes, sustainable order velocities will be tested.

Nov 2026▲Q3 results significantly beat expectations with strong organic growth in Life Sciences and software. AI demand is demonstrably expanding beyond initial use cases.
Aug 2026→The Q2 2026 10-Q filing confirmed the recent positive trends and margin recovery without materially altering the broader investment thesis.
Aug 2026▲Q2 results showed margins bouncing back to 29.3 percent. A new structural AI catalyst emerged, and the China divestiture agreement was officially signed.
May 2026→Q1 2026 confirmed a mixed setup. Revenue improved and the China Immunodiagnostics exit could help the future mix, but margins contracted sharply in both segments.
May 2026▲Management announced plans to divest the China Immunodiagnostics business, which was about 6 percent of total company revenue last year. That makes the long term story cleaner if the sale closes.
Feb 2026▼The 2025 10-K showed Life Sciences Solutions declined for the year and margins fell in both segments. It also added goodwill risk, with the Life Sciences Solutions unit close to its impairment threshold.
Nov 2025▼Q3 2025 weakened the recovery case because Life Sciences Solutions slipped back to a revenue decline. Margin contraction also accelerated across both segments.
Aug 2025→Q2 2025 showed Life Sciences Solutions returning to slight growth, a useful sign after weakness. The benefit was offset by another quarter of margin pressure.
02 Business model

Tools, tests, and repeat use

Revvity makes money by selling instruments, reagents, consumables, software, and services. Instruments are the expensive lab machines. Reagents and consumables are the items customers use again and again in testing workflows.

The company serves two broad customer groups. Life Sciences sells into research and drug development. Diagnostics sells into clinical testing areas such as immunodiagnostics and reproductive health.

The model works best when Revvity becomes a permanent part of a customer lab. That creates repeat sales and high switching costs. It breaks when customers delay lab spending or when the company has to sell a lower margin product mix.

03 Product portfolio

What Revvity sells

Steady

Life Sciences Solutions

This includes reagents, consumables, and instruments like the Opera Phenix OptIQ. AI validation tools have created a massive backlog here.

Growth engine

Software

Software helps labs manage data and workflows. It rebounded to upper teens growth recently, driven by Signals AI and new AI native tools.

Cash cow

Immunodiagnostics

This business sells tools and tests used in clinical diagnostics. The business excluding China continues to accelerate.

Growth engine

Reproductive Health

This standout segment of Diagnostics includes newborn screening and the new GSP T1D 3-Plex kit for early diabetes detection.

Option

China Immunodiagnostics

Revvity signed a definitive agreement to sell this business by late 2027 to reduce exposure to Chinese policy pressure.

04 Business segments

Two segments, almost even size

Life Sciences51%modest
Diagnostics49%modest

Segment mix reflects recent historical revenue where Life Sciences and Diagnostics are roughly split at 51 percent and 49 percent. The planned China Immunodiagnostics divestiture will alter this mix once closed.

05 Risk factors

What could go wrong

Bulk order timing flatters growth

Low impact · Medium odds

Some of the third quarter reagent strength was aided by the timing of bulk screening orders. This adds a benefit that may flatter the underlying run rate. The company must show that sequential reagent demand remains strong without these bulk benefits.

We watchSequential run rate reagent demand in Q4 and beyond.

Instrument backlog normalization

Medium impact · Medium odds

Instrument growth is currently supported by executing on a large backlog of orders. Once this backlog normalizes, it raises questions about sustainable order velocities. Management must prove that new AI demand can replace the backlog consumption.

We watchInstrument order rates and book to bill ratios.

China divestiture execution

Medium impact · Low odds

A definitive agreement is signed, but the deal does not close until late 2027. Any regulatory delays or stranded costs could disrupt operations and limit the strategic benefit of the sale.

We watchDeal closing milestones and management comments on stranded costs.

Goodwill impairment in Life Sciences Solutions

Medium impact · Low odds

The Life Sciences Solutions unit has a massive $4.5 billion goodwill balance. While the recent growth rebound heavily reduces the near term probability of a charge, the fair value buffer remains narrow.

We watchAny formal updates to the goodwill impairment buffer in the next 10-K.
06 Quick answers

In one breath

What does Revvity do?

Revvity sells tools used in health science research and clinical testing. Its products include instruments, reagents, consumables, software, diagnostics tools, and services.

Why is Revvity selling its China Immunodiagnostics business?

The business faces heavy policy pressure in China. Revvity is selling it to focus capital on higher growth, higher return areas of health sciences.

Is Revvity growing again?

Yes. The core Life Sciences segment returned to 9 percent organic growth in the third quarter, while Signals software surged to upper teens growth.

What is the biggest risk for Revvity stock?

A key risk is whether recent growth was pulled forward by bulk orders or supported unsustainably by backlogs. The company needs to prove order velocity can remain high once backlogs clear.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Revvity Q3 2026 earnings call transcript
  2. Revvity Q2 2026 Form 10-Q
  3. Revvity Q1 2026 Form 10-Q
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near Revvity, Inc. in Finn's Diagnostics & Research industry ranking.

Get started with Finn today